Skip to content


Honeymoon trends for 2019: 7 ideas to have the trip of a lifetime

Posted in Travel & Living

As much as you’ve been waiting for (and planning) your wedding day, you’ve probably also been daydreaming about your honeymoon since you got engaged. How can we blame you?! That’s our favourite part too! Since we don’t want you to have just an average vacation, here’s a list of the 7 top honeymoon trends for 2019.

Tactile ASL, talking hands

Posted in Technology & Research

On the NoisyVision website we did not talk often about Sign Language. Yet among our members and friends there are people who use this way of communicating.
Deafblind people may not have access to our channels and so it is difficult for us to reach them. Perhaps it was meant for Chiara to find us. She knows the tactile ASL and she could be the bridge between NoisyVision and this world of silence and darkness, because we also want to address the deafblind and communicate with them.
Here is the story of how Chiara learned the ASL Tactile 

See Bad, Feel Good. The book by Krister Inde

Posted in Technology & Research

In June 2018 I had the pleasure of meeting Krister Inde in person. We were in Laško, Slovenia, both invited as speakers at the first low vision conference organized by the European Blind Union, the voice of the blind and partially sighted people in Europe
The thing that struck me about Krister is the lightness with which he speaks about visual impairment, not just with words, but with all of himself.
He conveys serenity. He is the impersonation of the title of his book, because he too is visually impaired but it is clearly perceived that he is serene and happy.

The Assistance Fund Opens New Program for Inherited Retinal Diseases

Posted in Technology & Research

The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today launched a new program that offers financial support for individuals with inherited retinal diseases. The fund will assist patients in paying out-of-pocket medical costs incurred as a result of their condition, including health insurance premiums, copayments and incidental medical expenses.

Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)

Posted in Technology & Research

Ophthotech Corporation (NASDAQ: OPHT) announced today that the first patient has been enrolled in the Phase 2b randomized, double masked, sham controlled clinical trial assessing the efficacy and safety of Zimura® (avacincaptad pegol), complement C5 inhibitor, in patients with autosomal recessive Stargardt disease (STGD1). STGD1 is an inherited orphan retinal disease causing vision loss during childhood or adolescence. Currently there are no FDA or EMA approved treatment options available for patients with STGD1. Over 30 sites have been identified for this clinical trial, making it one of the largest interventional clinical trials for STGD1 to date. The scientific details of the Stargardt clinical trial will be presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii.